Drug intelligence / Profile preview

B1655

Development stage: Unknown
Lead developer: Tasly Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

B1655 is a recombinant humanized monoclonal antibody developed by Tianjin Tasly Biopharmaceutical for the treatment of hypercholesterolemia. It functions as a PCSK9 inhibitor, binding to proprotein convertase subtilisin/kexin type 9 (PCSK9) to prevent the degradation of low-density lipoprotein receptors (LDLR) on the surface of hepatocytes. This action increases the density of LDLRs, facilitating the clearance of circulating low-density lipoprotein cholesterol (LDL-C). B1655 is currently being evaluated in Phase 3 clinical trials for patients with primary hypercholesterolemia and mixed dyslipidemia.

Other names: PCSK9 monoclonal antibodyPCSK-9 monoclonal antibodyPCSK 9 monoclonal antibody

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on B1655.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B1655.

Explore the full profile